{"id":409521,"date":"2025-10-17T14:51:47","date_gmt":"2025-10-17T12:51:47","guid":{"rendered":"https:\/\/medizinonline.com\/?p=409521"},"modified":"2025-10-20T11:44:32","modified_gmt":"2025-10-20T09:44:32","slug":"tepkinly-desormais-aussi-autorise-en-cas-de-lymphome-folliculaire-recidivant-refractaire-a-partir-de-la-3e-ligne-de-traitement","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/tepkinly-desormais-aussi-autorise-en-cas-de-lymphome-folliculaire-recidivant-refractaire-a-partir-de-la-3e-ligne-de-traitement\/","title":{"rendered":"Tepkinly\u00ae d\u00e9sormais aussi autoris\u00e9 en cas de lymphome folliculaire r\u00e9cidivant\/r\u00e9fractaire \u00e0 partir de la 3e\u00a0ligne de traitement"},"content":{"rendered":"\n<p><strong><strong>Depuis le 19.08.2025, l\u2019anticorps bisp\u00e9cifique Tepkinly\u00ae (epcoritamab) est autoris\u00e9 en monoth\u00e9rapie pour le traitement des patient-e-s adultes atteint-e-s d\u2019un lymphome folliculaire r\u00e9cidivant ou r\u00e9fractaire (LF&nbsp;R\/R), qui ont re\u00e7u auparavant au moins deux&nbsp;lignes de traitement syst\u00e9mique [1]. L\u2019autorisation repose sur les donn\u00e9es de l\u2019\u00e9tude&nbsp;EPCORE&nbsp;NHL-1, qui montre \u00e9galement une r\u00e9ponse profonde et persistante apr\u00e8s 3&nbsp;ans de suivi dans une population h\u00e9t\u00e9rog\u00e8ne de patient-e-s atteint-e-s d\u2019un LF&nbsp;R\/R lourdement pr\u00e9trait\u00e9-e-s [2, 3].<\/strong><\/strong><\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Ftepkinly-desormais-aussi-autorise-en-cas-de-lymphome-folliculaire-recidivant-refractaire-a-partir-de-la-3e-ligne-de-traitement%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Depuis le 19.08.2025, l\u2019anticorps bisp\u00e9cifique Tepkinly\u00ae (epcoritamab) est autoris\u00e9 en monoth\u00e9rapie pour le traitement des patient-e-s adultes atteint-e-s d\u2019un lymphome folliculaire r\u00e9cidivant ou r\u00e9fractaire (LF&nbsp;R\/R), qui ont re\u00e7u auparavant au&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Ftepkinly-desormais-aussi-autorise-en-cas-de-lymphome-folliculaire-recidivant-refractaire-a-partir-de-la-3e-ligne-de-traitement%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":17461,"featured_media":409395,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":" Contenu sponsoris\u00e9: Lymphome folliculaire","footnotes":""},"category":[11523,11345,11373,11389,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-409521","post","type-post","status-publish","format-standard","has-post-thumbnail","category-actualites","category-contenu-des-partenaires","category-hematologie","category-oncologie","category-rx-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-15 20:21:28","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/409521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/17461"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=409521"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/409521\/revisions"}],"predecessor-version":[{"id":410113,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/409521\/revisions\/410113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/409395"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=409521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=409521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=409521"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=409521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}